Колин Кэмпбелл - Китайское исследование: обновленное и расширенное издание. Классическая книга о здоровом питании [litres]

Newman B., Mu H., Butler L. M., et al. “Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.” JAMA 279 (1998): 915–921.

Antoniou A., Pharoah P. D. P., Narod S., et al. “Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.” Am. J. Hum. Genet. 72 (2003): 1117–1130.

Tabar L., Fagerberg G., Chen H. H., et al. “Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial.” Cancer 75 (1995): 2507–2517.

Bjurstram N., Bjorneld L., Duffy S. W., et al. “The Gothenburg Breast Cancer Screening Trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization.” Cancer 80 (1997): 2091–2099.

Frisell J., Lidbrink E., Hellström L., and Rutqvist L. E. “Follow-up after 11 years: update of mortality results in the Stockholm mammographic screening trial.” Breast Cancer Res. Treat 45 (1997): 263–270.

Greenlee R. T., Hill-Harmon M. B., Murray T., et al. “Cancer statistics, 2001.” CA Cancer J. Clin. 51 (2001): 15–36.

Cairns J. “The treatment of diseases and the war against cancer.” Sci. Am. 253 (1985): 31–39.

Cuzick J., and Baum M. “Tamoxifen and contralateral breast cancer.” Lancet 2 (1985): 282.

Cuzick J., Wang D. Y., and Bulbrook R. D. “The prevention of breast cancer.” Lancet 1 (1986): 83–86.

Fisher B., Costantino J. P., Wickerham D. L., et al. “Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P 1 Study.” J. Nat. Cancer Inst. 90 (1998): 1371–1388.

Freedman A. N., Graubard B. I., Rao S. R., et al. “Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention.” J. Nat. Cancer Inst. 95 (2003): 526–532.

Powles T., Eeles R., Ashley S., et al. “Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.” Lancet 352 (1998): 98–101.

Veronesi U., Maisonneuve P., Costa A., et al. “Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.” Lancet 352 (1998): 93–97.

Freedman A. N., Graubard B. I., Rao S. R., et al. “Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention.” J. Nat. Cancer Inst. 95 (2003): 526–532.

Cuzick J. “A brief review of the current breast cancer prevention trials and proposals for future trials.” Eur. J. Cancer 36 (2000): 1298–1302.

Cummings S. R., Eckert S., Krueger K. A., et al. “The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial.” JAMA 281 (1999): 2189–2197.

Bernstein L., and Ross R. K. “Endogenous hormones and breast cancer risk.” Epidemiol. Revs. 15 (1993): 48–65.

Pike M. C., Spicer D. V., Dahmoush L., et al. “Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.” Epidemiol. Revs. 15 (1993): 17–35.

Dorgan J. F., Hunsberger S. A., McMahon R. P., et al. “Diet and sex hormones in girls: findings from a randomized controlled clinical trial.” J. Nat. Cancer Inst. 95 (2003): 132–141.

Dorgan J. F., Hunsberger S. A., McMahon R. P., et al. “Diet and sex hormones in girls: findings from a randomized controlled clinical trial.” J. Nat. Cancer Inst. 95 (2003): 132–141.

Ornish D., Scherwitz L. W., Billings J. H., et al. “Intensive lifestyle changes for reversal of coronary heart disease.” JAMA 280 (1998): 2001–2007.

Esselstyn C. B., Ellis S. G., Medendorp S. V., et al. “A strategy to arrest and reverse coronary artery disease: a 5-year longitudinal study of a single physician’s practice.” J. Family Practice 41 (1995): 560–568.

Ornish D., Weidner G., Fair W. R., et al. “Intensive lifestyle changes may affect the progression of prostate cancer.” J. Urol. 174 (2005): 1065–1069; обсуждение 1069–1070.

Hildenbrand G. L. G., Hildenbrand L. C., Bradford K., et al. “Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review.” Alternative Therapies in Health and Medicine 1 (1995): 29–37.

Youngman L. D., and Campbell T. C. “Inhibition of aflatoxin B1-induced gamma-glutamyl transpeptidase positive (GGT+) hepatic preneoplastic foci and tumors by low protein diets: evidence that altered GGT+ foci indicate neoplastic potential.” Carcinogenesis 13 (1992): 1607–1613.

Ronai Z., Gradia S., El-Bayoumy K., et al. “Contrasting incidence of ras mutations in rat mammary and mouse skin tumors induced by anti-benzo[c]phenanthrene 3,4-diol 1,2-epoxide.” Carcinogenesis 15 (1994): 2113–2116.

Jeffy B. D., Schultz E. U., Selmin O., et al. “Inhibition of BRCA 1 expression by benzo[a] pyrene and diol epoxide.” Mol. Carcinogenesis 26 (1999): 100–118.

Gammon M. D., Santella R. M., Neugut A. I., et al. “Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts.” Cancer Epidemiol. Biomarkers Prev. 11 (2002): 677–685.

Gammon M. D., Santella R. M., Neugut A. I., et al. “Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts.” Cancer Epidemiol. Biomarkers Prev. 11 (2002): 677–685.

Gammon M. D., Wolff M. S., Neugut A. I., et al. “Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood.” Cancer Epidemiol. Biomarkers Prev. 11 (2002): 686–697.

Gray J., Evans N., Taylor B., Rizzo J., and Walker M. “State of the evidence: the connection between breast cancer and the environment.” Int. J. Occup. Environ. Health 15 (2009): 43–78; Brophy J. T., et al. “Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study.” Environ. Health 11 (2012): 1–17.

Brophy J. T., et al. “Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study.” Environ. Health 11 (2012): 1–17.

Gray J., Evans N., Taylor B., Rizzo J., and Walker M. “State of the evidence: the connection between breast cancer and the environment.” Int. J. Occup. Environ. Health (2009): 15, 43–78.

Michels K. B., Mohllajee A. P., Roset-Bahmanyar E., Beehler G. P., and Moysich K. B. “Diet and breast cancer. A review of the prospective observational studies.” Cancer 109 (2007): 2712–2749.

Campbell T. C., and Hayes J. R. “Role of nutrition in the drug metabolizing system.” Pharmacol. Revs. 26 (1974): 171–197; Campbell T. C., and Hayes J. R. “The effect of quantity and quality of dietary protein on drug metabolism.” Fed. Proc. 35 (1976): 2470–2474.

Weatherholz W. M., Campbell T. C., and Webb R. E. “Effect of dietary protein levels on the toxicity and metabolism of heptaclor.” J. Nutr. 98 (1969): 90–94.

Mgbodile M. U. K., Hayes J. R., and Campbell T. C. “Effect of protein deficiency on the inducibility of the hepatic microsomal drug-metabolizing enzyme system. II. Effect on enzyme kinetics and electron transport system.” Biochem. Pharmacol. 22 (1973): 1125–1132; Hayes J. R., and Campbell T. C. “Effect of protein deficiency on the inducibility of the hepatic microsomal drug-metabolizing enzyme system. III. Effect of 3-methylcholanthrene induction on activity and binding kinetics.” Biochem. Pharmacol. 23 (1974): 1721–1732.

Huang H. H., Hawrylewicz E. J., Kissane J. Q., and Drab E. A. “Effect of protein diet on release of prolactin and ovarian steroids in female rats.” Nutr. Rpts. Int. 26 (1982): 807–820.

Rose D. P., Goldman M., Connolly J. M., and Strong L. E. “High-fiber diet reduces serum estrogen concentrations in premenopausal women.” Am. J. Clin. Nutr. 54 (1991): 520–525.

Rose D. P., Boyar A. P., Cohen L., and Strong, L. E. “Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins.” J. Natl. Cancer Inst. 78 (1987): 623–626.

Humphries K. H., and Gill S. “Risks and benefits of hormone replacement therapy: the evidence speaks.” Canadian Med. Assoc. J. 168 (2003): 1001–1010.

Humphries K. H., and Gill S. “Risks and benefits of hormone replacement therapy: the evidence speaks.” Canadian Med. Assoc. J. 168 (2003): 1001–1010.

Рабочая группа в рамках инициативы по охране здоровья женщин / Writing Group for the Women’s Health Initiative Investigators. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (2002): 321–333.

Hulley S., Grady D., Bush T., et al. “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.” JAMA 280 (1998): 605–613.

Хотя данный результат не является статистически значимым, его соответствие выводам Инициативы по охране здоровья женщин поражает.

Humphries K. H., and Gill S. “Risks and benefits of hormone replacement therapy: the evidence speaks.” Canadian Med. Assoc. J. 168 (2003): 1001–1010.

Рабочая группа в рамках инициативы по охране здоровья женщин / Writing Group for the Women’s Health Initiative Investigators. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (2002): 321–333.

Рабочая группа в рамках инициативы по охране здоровья женщин / Writing Group for the Women’s Health Initiative Investigators. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (2002): 321–333.